WallStSmart

Brookfield Business Partners LP (BBU)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Brookfield Business Partners LP generates 10505% more annual revenue ($27.46B vs $258.90M). BBU leads profitability with a -0.1% profit margin vs -15.5%. BBU earns a higher WallStSmart Score of 52/100 (C-).

BBU

Buy

52

out of 100

Grade: C-

Growth: 4.7Profit: 5.0Value: 5.0Quality: 4.3
Piotroski: 3/9

ZEPP

Hold

43

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BBU2 strengths · Avg: 9.0/10
EPS GrowthGrowth
80.0%10/10

Earnings expanding 80.0% YoY

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

BBU4 concerns · Avg: 2.3/10
Return on EquityProfitability
2.4%3/10

ROE of 2.4% — below average capital efficiency

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Revenue GrowthGrowth
-4.5%2/10

Revenue declined 4.5%

Profit MarginProfitability
-0.1%1/10

Currently unprofitable

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$216.30M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : BBU

The strongest argument for BBU centers on EPS Growth, Price/Book.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : BBU

The primary concerns for BBU are Return on Equity, Piotroski F-Score, Revenue Growth. Debt-to-equity of 19.07 is elevated, increasing financial risk.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

BBU profiles as a turnaround stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.59 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor CONGLOMERATES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BBU scores higher overall (52/100 vs 43/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Brookfield Business Partners LP

INDUSTRIALS · CONGLOMERATES · USA

Brookfield Business Partners LP (BBU) is a leading global alternative asset manager that focuses on acquiring, operating, and enhancing a diversified portfolio of high-quality, cash-generating businesses. Capitalizing on the robust resources and expertise of its parent company, Brookfield Asset Management, BBU strategically invests in sectors such as industrials, utilities, and consumer products, employing a disciplined approach to operational improvements. With an emphasis on delivering sustainable cash distributions and capital appreciation, BBU is well-equipped to capitalize on growth opportunities, positioning itself to generate superior returns for its investors over the long term.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?